Becton DickinsonBDX +2.44%76 Buyback Yield % is 5.53 as of Jun. 25, 2026, which is 521% above its 10-year median of 0.89. GuruFocus rates BDX with a GF Score™ of 76/100 and a GF Value™ of $191.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 346 Medical Devices & Instruments companies, Becton Dickinson ranks better than 96.53% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Becton Dickinson's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Becton Dickinson's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Becton Dickinson Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Becton Dickinson's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Becton Dickinson's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Becton Dickinson (BDX) has a Buyback Yield % of 5.53 as of Jun. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Becton Dickinson and its competitors. This is 521% above median its historical median of 0.89. According to the industry distribution chart, Becton Dickinson ranks #12 out of 346 companies in the Medical Devices & Instruments industry, placing it in the top 3.5%.
Is Becton Dickinson's Buyback Yield % too high?
Becton Dickinson's current Buyback Yield % of 5.53 is 521% above median its 10-year median of 0.89. Based on the distribution chart, Becton Dickinson ranks #12 out of 346 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Becton Dickinson has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's Buyback Yield % compare to MDLN and RMD?
According to the Medical Devices & Instruments industry distribution chart, Becton Dickinson ranks #12 out of 346 companies for Buyback Yield %. This places Becton Dickinson in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Becton Dickinson and its competitors. Becton Dickinson's current Buyback Yield % is 5.53, which is 521% above median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Based on GuruFocus' analysis, Becton Dickinson (BDX) is currently considered Modestly Undervalued. The stock's GF Value™ is $191.05, compared to a current price of $151.38 — trading 20.8% below its estimated fair value. The current Buyback Yield % is 5.53, which is 521% above median its 10-year median of 0.89. Becton Dickinson's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Becton Dickinson (BDX), the current Buyback Yield % is 5.53 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Becton Dickinson (BDX) Overvalued in 2026?
Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued.
The current stock price of $151.38 is trading 20.8% below its estimated GF Value™ of $191.05.
GuruFocus considers Becton Dickinson to be Modestly Undervalued.
Key valuation signals for BDX:
Buyback Yield %: 5.53 (521% above median its 10-year median of 0.89)
GF Value™: $191.05 vs. price of $151.38 (20.8% below fair value)
No single metric tells the full story. See the BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
76GF Score
Get the complete analysis for BDX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDX has been successfully added to your 
